These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26242222)

  • 21. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
    Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
    Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine.
    Botticelli A; Scagnoli S; Roberto M; Lionetto L; Cerbelli B; Simmaco M; Marchetti P
    J Oncol Pharm Pract; 2020 Dec; 26(8):1836-1842. PubMed ID: 32131682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results.
    Honda J; Sasa M; Moriya T; Bando Y; Hirose T; Takahashi M; Nagao T; Tangoku A
    J Med Invest; 2008 Feb; 55(1-2):54-60. PubMed ID: 18319546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients.
    Dogan M; Karabulut HG; Tukun A; Demirkazik A; Utkan G; Yalcin B; Dincol D; Akbulut H; Icli F
    Asian Pac J Cancer Prev; 2012; 13(4):1553-6. PubMed ID: 22799365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
    van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
    Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of real-time reverse-transcription-polymerase chain reaction for quantification of capecitabine-metabolizing enzymes.
    Macpherson JS; Jodrell DI; Guichard SM
    Anal Biochem; 2006 Mar; 350(1):71-80. PubMed ID: 16438929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
    Garcia AA; Blessing JA; Lenz HJ; Darcy KM; Mannel RS; Miller DS; Husseinzadeh N;
    Gynecol Oncol; 2005 Mar; 96(3):810-7. PubMed ID: 15721430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
    Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
    Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.
    Ribelles N; López-Siles J; Sánchez A; González E; Sánchez MJ; Carabantes F; Sánchez-Rovira P; Márquez A; Dueñas R; Sevilla I; Alba E
    Curr Drug Metab; 2008 May; 9(4):336-43. PubMed ID: 18473752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
    Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
    J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
    Amatori F; Di Paolo A; Del Tacca M; Fontanini G; Vannozzi F; Boldrini L; Bocci G; Lastella M; Danesi R
    Pharmacogenet Genomics; 2006 Nov; 16(11):809-16. PubMed ID: 17047489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans--toxicological implications.
    Shindoh H; Nakano K; Yoshida T; Ishigai M
    J Toxicol Sci; 2011 Aug; 36(4):411-22. PubMed ID: 21804305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Forced expression of cytidine deaminase confers sensitivity to capecitabine.
    Morita T; Matsuzaki A; Kurokawa S; Tokue A
    Oncology; 2003; 65(3):267-74. PubMed ID: 14657601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of target gene polymorphisms in 5-Fluorouracil toxicity: a case report.
    Scalvini A; Ferrari V; Bodei S; Arcangeli G; Consoli F; Spano P; Sigala S
    Pharmacology; 2012; 89(1-2):99-102. PubMed ID: 22343422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
    Miwa M; Ura M; Nishida M; Sawada N; Ishikawa T; Mori K; Shimma N; Umeda I; Ishitsuka H
    Eur J Cancer; 1998 Jul; 34(8):1274-81. PubMed ID: 9849491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
    Shahrokni A; Rajebi MR; Harold L; Saif MW
    JOP; 2009 Mar; 10(2):215-20. PubMed ID: 19287123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model.
    Tsukamoto Y; Kato Y; Ura M; Horii I; Ishikawa T; Ishitsuka H; Sugiyama Y
    Biopharm Drug Dispos; 2001 Jan; 22(1):1-14. PubMed ID: 11745902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.
    Etienne MC; Ilc K; Formento JL; Laurent-Puig P; Formento P; Cheradame S; Fischel JL; Milano G
    Br J Cancer; 2004 Jan; 90(2):526-34. PubMed ID: 14735204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.